Literature DB >> 22305048

Human and porcine hepatitis E viruses, southeastern Bolivia.

Michael A Purdy, Maria Chiara Dell'Amico, José Luis Gonzales, Higinio Segundo, Francesco Tolari, Maurizio Mazzei, Alessandro Bartoloni, Yury E Khudyakov.   

Abstract

Entities:  

Mesh:

Year:  2012        PMID: 22305048      PMCID: PMC3310471          DOI: 10.3201/eid1802.111453

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Hepatitis E virus (HEV) genotypes 3 and 4 are considered to be primarily zoonotic (). However, recent data indicate that both genotypes can be transmitted among humans through other routes (,). Observations of genetic distinctiveness between swine and human HEV strains circulating within the same region argue against exclusivity of zoonotic transmission (). A recent report presented a remarkable example of such distinction between genotype 3 isolates in rural communities in southeastern Bolivia (). We examined HEV sequences obtained in that study to show the independent genetic origin of swine and human variants. Findings suggest disjunction between human and swine HEV strains in this epidemiologic setting, despite the potential for extensive cross-species exposure. Using reference sequences from Lu et al. (), we conducted subtype analysis of HEV open reading frame 2 sequences at nucleotide positions 826–1173 (GenBank accession no. AF060668) from isolates from 2 rural communities in southeastern Bolivia (). Analysis showed that swine sequences belonged to subtype 3i and that the human sequences belonged to 3e. We collected all available GenBank genotype 3 sequences covering this genomic region for which the dates of collection were documented. Sequences were used to estimate the time from the most recent common ancestor (tMRCA) by using BEAST version 1.6.1 (). Estimated tMRCA for GenBank sequences was longer than for sequences from Bolivia alone (Table) or for all genotype 3 sequences together (Table).
Table

Model estimates of time to most common recent ancestor for HEV ORF2 nucleotide sequences, southeastern Bolivia*

ModelStart positionStop positionBolivia sequenceGenBank sequenceMean tMRCA, y95% HPD, y
Mean ± SD rate of substitutions/site/y
LowerUpper
A8261173XNU55.3116.26108.053.27 × 10–3 ± 9.44 × 10–6
B8261173NU3i and 3e148.633.01291.461.88 × 10–2 ± 6.41 × 10–4
C8261173XX144.4538.66298.203.43 × 10–3 ± 4.74 × 10–5
D8261173NUX328.0545.59681.902.12 × 10–3 ± 7.33 × 10–5
E11980NUX296.06163.40467.979.27 × 10–4 ± 1.25 × 10–5
F82611733 seqsX275.4540.06635.322.40 × 10–3 ± 5.06 × 10–5

*HEV, hepatitis E virus; ORF, open reading frame; tMRCA, time to the most recent common ancestor; HPD, highest posterior density boundary; X, sequences was used; NU, not used; 3i and 3e, subtype 3i and 3e sequences were used; 3 seqs, sequences (CV2, CB9, and HB2BA053) from Bolivia were used.

*HEV, hepatitis E virus; ORF, open reading frame; tMRCA, time to the most recent common ancestor; HPD, highest posterior density boundary; X, sequences was used; NU, not used; 3i and 3e, subtype 3i and 3e sequences were used; 3 seqs, sequences (CV2, CB9, and HB2BA053) from Bolivia were used. To reduce the effect of close relatedness among human or swine HEV sequences from Bolivia on the tMRCA estimate, we used only 1 representative sequence per species from each community in the final analysis. This analysis identified an estimated tMRCA similar to that seen for GenBank sequences alone (Table, model F vs. model D). This estimate indicates that human and swine HEV isolates from southeastern Bolivia last shared a common ancestor ≈275 years ago (Table, model F). Thus, swine HEV strains from both rural communities belonged to subtype 3i, and the human HEV strains identified from the community of Bartolo, Bolivia, belonged to subtype 3e and shared an ancestor with swine strains almost 3 centuries ago. This finding is surprising because the community of Bartolo has several potential risk factors for zoonotic transmission of HEV. There are ≈200 humans and ≈70 swine in Bartolo (). Residents are mainly native Quechua and Guarani with some of mixed Spanish ancestry who subsist at a low socioeconomic level. Their main livelihood activities are agriculture and breeding of animals. Free-range pig farms are family owned. Because of its impoverished state, the community has no running water, and few houses have toilets. No facilities are suitable for safely slaughtering animals (,). These conditions appear to create a setting in which zoonotic transmission of HEV should be common, and infection should be caused by a strain shared between swine and humans. However, the data suggest host-specific infection with distinct HEV subtypes. Although specimens were collected from 172 humans (≈86%) and 67 swine (≈96%) in Bartolo (), zoonotically transmitted isolates may have been missed because of the sample-pooling technique used (). Nevertheless, detection of distinct HEV strains in human and swine populations indicates possible nonzoonotic, human-to-human transmission in this community. Detection of antibodies against HEV among 7% of residents and HEV genomes in persons without serologic markers of HEV infection indicate a higher HEV prevalence in Bartolo (). Subclinical infection detected by PCR among Bartolo residents (), rapid decrease of HEV antibody, and uncertain sensitivity of commercial serologic assays () suggest that the reported extent of HEV infection is most likely an underestimate. High prevalence may generate conditions in this community that effectively prevent cross-species transmission because of frequent exposure to HEV early in life when contacts between humans and animals are limited, thus promoting host-specific transmission. This supposition is supported by the higher seropositivity seen among children 1–5 years of age and adults 41–50 years of age in Bartolo (). Implications of these observations for understanding HEV evolution and epidemiology of HEV infections warrant further research on genetic heterogeneity of HEV strains in this region and other epidemiologic settings.
  9 in total

Review 1.  Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis.

Authors:  Ling Lu; Chunhua Li; Curt H Hagedorn
Journal:  Rev Med Virol       Date:  2006 Jan-Feb       Impact factor: 6.989

2.  Swine and human hepatitis E virus (HEV) infection in China.

Authors:  Yu-Min Zhu; Shi-Juan Dong; Fu-Sheng Si; Rui-Song Yu; Zhen Li; Xiao-Ming Yu; Si-Xiang Zou
Journal:  J Clin Virol       Date:  2011-08-09       Impact factor: 3.168

3.  Prevalence of antibodies against hepatitis A and E viruses among rural populations of the Chaco region, south-eastern Bolivia.

Authors:  A Bartoloni; F Bartalesi; M Roselli; A Mantella; C C Arce; F Paradisi; A J Hall
Journal:  Trop Med Int Health       Date:  1999-09       Impact factor: 2.622

Review 4.  Serological diagnostics of hepatitis E virus infection.

Authors:  Yury Khudyakov; Saleem Kamili
Journal:  Virus Res       Date:  2011-06-15       Impact factor: 3.303

Review 5.  The molecular epidemiology of hepatitis E virus infection.

Authors:  Michael A Purdy; Yury E Khudyakov
Journal:  Virus Res       Date:  2011-05-11       Impact factor: 3.303

Review 6.  From barnyard to food table: the omnipresence of hepatitis E virus and risk for zoonotic infection and food safety.

Authors:  Xiang-Jin Meng
Journal:  Virus Res       Date:  2011-02-21       Impact factor: 3.303

7.  A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route.

Authors:  Keiji Matsubayashi; Jong-Hon Kang; Hidekatsu Sakata; Kazuaki Takahashi; Motohiro Shindo; Masaru Kato; Shinichiro Sato; Toshiaki Kato; Hiroyuki Nishimori; Kunihiko Tsuji; Hiroyuki Maguchi; Jun-Ichi Yoshida; Hiroshi Maekubo; Shunji Mishiro; Hisami Ikeda
Journal:  Transfusion       Date:  2008-07       Impact factor: 3.157

8.  Evolutionary history and population dynamics of hepatitis E virus.

Authors:  Michael A Purdy; Yury E Khudyakov
Journal:  PLoS One       Date:  2010-12-17       Impact factor: 3.240

9.  Hepatitis E virus genotype 3 in humans and Swine, Bolivia.

Authors:  Maria Chiara Dell'Amico; Annalisa Cavallo; José Luis Gonzales; Sara Irene Bonelli; Ybar Valda; Angela Pieri; Higinio Segund; Ramón Ibañez; Antonia Mantella; Filippo Bartalesi; Francesco Tolari; Alessandro Bartoloni
Journal:  Emerg Infect Dis       Date:  2011-08       Impact factor: 6.883

  9 in total
  5 in total

1.  Hepatitis E virus of subtype 3i in chronically infected kidney transplant recipients in southeastern France.

Authors:  Valérie Moal; René Gérolami; Audrey Ferretti; Raj Purgus; Patricia Devichi; Stéphane Burtey; Philippe Colson
Journal:  J Clin Microbiol       Date:  2014-09-03       Impact factor: 5.948

Review 2.  Hepatitis E virus infection.

Authors:  Nassim Kamar; Harry R Dalton; Florence Abravanel; Jacques Izopet
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

3.  Seroprevalence of Hepatitis A Virus, Hepatitis E Virus, and Helicobacter pylori in Rural Communities of the Bolivian Chaco, 2013.

Authors:  Irene Campolmi; Michele Spinicci; David Rojo Mayaregua; Herlan Gamboa Barahona; Antonia Mantella; Yunni Lara; Mimmo Roselli; Marianne Strohmeyer; Giampaolo Corti; Francesco Tolari; Joaquín Monasterio Pinckert; Harry R Dalton; Alessandro Bartoloni
Journal:  Am J Trop Med Hyg       Date:  2018-03-22       Impact factor: 2.345

4.  Hepatitis E Virus Genotype 3 in Colombia: Survey in Patients with Clinical Diagnosis of Viral Hepatitis.

Authors:  Julio Rendon; Maria Cristina Hoyos; Diana di Filippo; Fabian Cortes-Mancera; Carolina Mantilla; Maria Mercedes Velasquez; Maria Elsy Sepulveda; Juan Carlos Restrepo; Sergio Jaramillo; Maria Patricia Arbelaez; Gonzalo Correa; Maria-Cristina Navas
Journal:  PLoS One       Date:  2016-02-17       Impact factor: 3.240

5.  Genetic host specificity of hepatitis E virus.

Authors:  James Lara; Michael A Purdy; Yury E Khudyakov
Journal:  Infect Genet Evol       Date:  2014-03-22       Impact factor: 3.342

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.